&nbsp;

Jun 2019

Drug

thalidomide

Other Name(s): Thalomid®

Quick Link(s):

Jun 2019

Drug

aXitinib

Other Name(s): Inlyta®

Quick Link(s):

Apr 2024

Drug

trametinib

Other Name(s): Mekinist®

Quick Link(s):

Sep 2021

Drug

AFAtinib

Other Name(s): Giotrif®

Quick Link(s):

Apr 2024

Drug

alectinib

Other Name(s): Alecensaro®

Quick Link(s):

Apr 2024

Regimen

AXIT

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

Exceptional Access Program

aXitinib - For second or third line treatment of advanced renal cell carcinoma, according to clinical criteria

Drugs Used:

aXitinib

Quick Link(s):

Regimen Monograph

Apr 2024

Regimen

TRAM

Cancer Type:

Skin,

Melanoma

Intent: Palliative

Funding:

Exceptional Access Program

trametinib - As monotherapy in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, according to specific criteria

Drugs Used:

trametinib

Quick Link(s):

Regimen Monograph

Jun 2021

Regimen

AFAT

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

Exceptional Access Program

AFAtinib - For first-line monotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC), according to specific criteria

Drugs Used:

AFAtinib

Quick Link(s):

Regimen Monograph

Apr 2024

Regimen

ALEC

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

Exceptional Access Program

alectinib - Treatment of non-small cell lung cancer, according to specific criteria

Drugs Used:

alectinib

Quick Link(s):

Regimen Monograph

Apr 2024

Regimen

ATRA(IND)

Cancer Type:

Hematologic,

Leukemia - Acute Promyelocytic (APL)

Intent: Palliative, Curative

Funding:

Exceptional Access Program

tretinoin (ATRA)

Drugs Used:

tretinoin (ATRA)

Quick Link(s):

Regimen Monograph

May 2019

Regimen

ATRA(MNT)

Cancer Type:

Hematologic,

Leukemia - Acute Promyelocytic (APL)

Intent: Curative, Palliative

Funding:

Exceptional Access Program

tretinoin (ATRA)

Drugs Used:

tretinoin (ATRA)